Search

Your search keyword '"A. Arlt"' showing total 316 results

Search Constraints

Start Over You searched for: Author "A. Arlt" Remove constraint Author: "A. Arlt" Journal endocrine abstracts Remove constraint Journal: endocrine abstracts
316 results on '"A. Arlt"'

Search Results

2. Biochemical control with dose reduction in chronic glucocorticoid therapy over 4 years: A phase III extension study of Chronocort (Efmody) in the treatment of Congenital Adrenal Hyperplasia (CAH)

3. Combined [18F]Fluorodeoxyglucose PET and [123I]Iodometomidate-SPECT for diagnostic evaluation of indeterminate adrenal neoplasias - The prospective cross-sectional diagnostic test performance study FAMIAN

4. The differential impact of oral classic and 11-oxygenated androgen precursor administration on downstream androgen metabolism and insulin sensitivity in women with polycystic ovary syndrome

5. Primary unilateral macronodular adrenal hyperplasia with concomitant glucocorticoid and androgen excess and KDM1A inactivation

6. CHAMPAIN study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency

7. Morning cortisol levels in patients with established primary adrenal insufficiency

8. 'Pseudo-failure' of adrenal vein sampling due to cortisol co-secretion by KCNJ5-mutant adenoma, and prediction of complete clinical success by urine hybrid steroid assay

9. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control

10. Machine learning-based steroid metabolome analysis reveals three distinct subtypes of polycystic ovary syndrome and implicates 11-oxygenated androgens as major drivers of metabolic risk

12. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control

13. Machine learning-based steroid metabolome analysis reveals three distinct subtypes of polycystic ovary syndrome and implicates 11-oxygenated androgens as major drivers of metabolic risk

15. Steroid and global metabolome in benign adrenal tumours with mild autonomous cortisol secretion: analysis by mass spectrometry and machine learning to understand metabolic risk

17. Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years

19. Simulation via Instant Messaging - Birmingham Advance helps to narrow the gap of knowledge and expectations between clinicians and women with polycystic ovary syndrome: A SIMBA-PCOS mixed-method study

22. Comparison of prednisolone and modified-release hydrocortisone capsules in the treatment of congenital adrenal hyperplasia: dose and disease control

24. Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years

25. Simulation via Instant Messaging - Birmingham Advance helps to narrow the gap of knowledge and expectations between clinicians and women with polycystic ovary syndrome: A SIMBA-PCOS mixed-method study

28. Steroid and global metabolome in benign adrenal tumours with mild autonomous cortisol secretion: analysis by mass spectrometry and machine learning to understand metabolic risk

30. Resistance to thyroid hormone alpha: molecular, biochemical and physiological approach to diagnosis and therapy

31. Combining steroid and global metabolome profiling by mass spectrometry with machine learning to investigate metabolic risk in benign adrenal tumours with mild autonomous cortisol secretion

33. Improved biochemical control with modified-release hydrocortisone overturns the impaired fludrocortisone effect in salt-wasting CAH patients

34. Simulation via instant messaging − birmingham advance (SIMBA) as a tool to bridge gaps in clinical knowledge and expectations between physicians and patients with polycystic ovary syndrome

35. Blue Morpho: An international survey investigating differences in emotional and psychosexual wellbeing by ethnicity and birthplace in women with polycystic ovary syndrome

37. SIMBA for Students: teaching preclinical medical and pharmacy students endocrinology through online simulation - a pilot study

45. Modified release hydrocortisone capsules (MRHC, Efmody) improve control of congenital adrenal hyperplasia (CAH) on a lower glucocorticoid dose than standard treatment

47. Fertility in congenital adrenal hyperplasia (CAH) patients on modified release hydrocortisone capsules (MRHC, Efmody)

49. A systematic review and meta-analysis assessing psychosexual wellbeing in people with polycystic ovary syndrome

50. Perceptions and experiences of women with polycystic ovary syndrome- a systematic review

Catalog

Books, media, physical & digital resources